ACAD ACADIA Pharmaceuticals Inc.

23.58
+0.26  (+1%)
Previous Close 23.32
Open 23.27
Price To Book 7.08
Market Cap 3392746544
Shares 143,882,381
Volume 2,197,676
Short Ratio
Av. Daily Volume 1,430,256

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 1H 2019.
Pimavanserin
Adjunctive Treatment in Patients With Major Depressive Disorder
Phase 2 initiated November 2016. Enrolment to be completed 2H 2019.
Pimavanserin - Advance
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 data due mid-2019.
Pimavanserin - Enhance
Adjunctive treatment of schizophrenia
Announced October 4, 2017 that trial will be discontinued.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin
Parkinson’s disease psychosis (PDP)
Phase 3 interim data 2H 2019 with final data due 2020.
Pimavanserin - Harmony
Alzheimer’s disease psychosis
Phase 3 trial to be initiated 2H 2019.
Trofinetide
Rett Syndrome

Latest News

  1. ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
  2. ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
  3. See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
  4. ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
  5. ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
  6. Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
  7. The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO
  8. Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
  9. HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
  10. Is ACADIA Pharmaceuticals Inc.’s (NASDAQ:ACAD) Liquidity Good Enough?
  11. Edited Transcript of ACAD earnings conference call or presentation 26-Feb-19 10:00pm GMT
  12. Why Acadia Pharmaceuticals Stock Perked Up in February
  13. ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019
  14. 3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks
  15. Acadia Pharmaceuticals Inc (ACAD) Q4 2018 Earnings Conference Call Transcript
  16. ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  17. Big Pharma faces the Senate in drug price hearings
  18. ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
  19. What's in the Cards for Bausch Health (BHC) Q4 Earnings?